Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides

Therapeutic Drug Monitoring

Volumn 20, Issue 5, 1998, Pages 473-477

  MacGowan, Alasdair P ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Pharmacodynamics; Teicoplanin; Therapeutic drug monitoring; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; PHARMACODYNAMICS; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DRUG MONITORING; HUMANS; TEICOPLANIN; VANCOMYCIN;

EID: 0031662683     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199810000-00005     Document Type: Conference Paper

References (59)

1. Gould IM. Pharmacodynamics and the relationship between in vitro and in vivo activity of antimicrobial agents. J Chemother 1997;9:74-83.
2. Bundtzen RW, Gerber AU, Hohn DL, et al. Post antibiotic suppression of bacterial growth. Rev Infect Dis 1981;3:28-37.
3. MacKenzie FM, Gould IM. The post antibiotic effect. J Antimicrob Chemother 1993;32:519-37.
4. Hanberger H, Nilsson LE, Nilsson M, et al. Post antibiotic effect of beta lactams antibiotics on Gram-negative bacteria in relation to morphology, initial killing and MIC. Eur J Clin Microbiol Infect Dis 1991;10:927-34.
5. Hanberger H. Pharmacodynamic effects of antibiotics: Studies on bacterial morphology, initial killing, post antibiotic effect and effective regrowth time. Scand J Infect Dis 1992;81:3-52.
6. Totsuka K, Kuchi K, Shimizu K, et al. Post antibiotic effect and clinical evaluation of teicoplanin. Nippon Kagaku Ryoho Gakki Zasshi 1993;41:173-7.
7. Cooper MA, Jin YF, Ashby JP, et al. In vitro comparison of the post-antibiotic effect of vancomycin and teicoplanin. J Antimicrob Chemother 1990;26:203-7.
8. Odenholt-Tornqvist I, Lowdin E, Cars O. Post antibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin and amikacin. Antimicrob Agents Chemother 1992;36:1852-8.
9. Larsson AJ, Walker KJ, Raddatz JK, et al. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 1996;38:589-97.
10. Bailey EM, Rybak MJ, Kaatz GW. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother 1991;35:1089-92.
11. Contrepois A, Joly V, Abel L, et al. The pharmacokinetics and extravascular diffusion of teicoplanin in rabbits and comparative efficacy with vancomycin in an experimental endocarditis model. J Antimicrob Chemother 1988;21:621-31.
12. Chambers HF, Kennedy S. Effect of dosage, peak and trough concentra-tions in serum, protein binding and bactericidal rate on efficacy of teicoplanin in a rabbit model with endocarditis. Antimicrob Agents Chemother 1990;34:510-4.
13. Knudsen JD, Fuursted K, Espersen F, et al. Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrob Agents Chemother 1997; 41:1910-5.
14. Duffull SB, Begg EJ, Chambers ST, et al. Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with dynamic in vitro model. Antimicrob Agents Chemother 1994;38:2480-2.
15. MacGowan AP, Bowker KE. Pharmacodynamics of antimicrobial agents and rationale for their dosing. J Chemother 1997;9:64-73.
16. Moellering RC, Krogstad DJ, Greenblatt DJ. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Rev Infect Dis 1981;3:S230-5.
17. Matzke GR, McGory RW, Halstenson CE, et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984;25:433-7.
18. Cunha BA, Quintiliani R, Deglin JM, et al. Pharmacokinetics of vancomycin in anuria. Rev Infect Dis 1981;3:5269-72.
19. Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982;21:575-80.
20. Vance-Bryan K, Guay DRP, Gilliland SS, et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993;37:436-40.
21. Brown N, Ho DHW, Fong KLL, et al. Effect of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother 1983;23:603-9.
22. Magera RE, Arroyo JC, Rosansky SJ, et al. Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis. Antimicrob Agents Chemother 1983;23:710-4.
23. Blevins RD, Halstenson CE, Salem NG, et al. Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agent Chemother 1984;25:603-6.
24. Touchette MA, Patel RV, Anandan JV, et al. Vancomycin removal by high-flux polysulfone haemodialysis membranes in critically ill patients with end-stage renal disease. Am J Kidney Dis 1995;26: 469-74.
25. Bressolle F, Kinowski JM, de la Coussaye JE, et al. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet 1994;26:457-71.
26. Alwakell J, Najjar Ta, al Yama MJ, et al. Comparison of the effects of three haemodialysis membranes on vancomycin disposition. Int Urol Nephrol 1994;26:223-8.
27. Santre C, Levoy O, Simon M, et al. Pharmacokinetics of vancomycin during continuous haemodiafiltration. Intensive Care Med 1993;19:347-80.
28. Le Normand Y, Milpied N, Kerguevis MF, et al. Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patients. Int J Biomed Comput 1994;36:121-5.
29. Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J 1995;14: 667-73.
30. Seay RE, Brundage RC, Jensen PD, et al. Population pharmacokinetics of vancomycin in neonates. Clin Pharmacol ther 1994;56: 169-75.
31. Rotschafer JC, Crossley K, Zaske D, et al. Pharmacokinetics of vancomycin: Observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother 1982;22:391-4.
32. Pou L, Rosell M, Lopez R, et al. Changes in vancomycin pharmacokinetics during treatment. Ther Drug Monit 1996;18:149-53.
33. -1. Biopharm Drug Dispos 1992;13:571-81.
34. Derbyshire N, Webb DB, Roberts D, et al. Pharmacokinetics of teicoplanin in subjects with varying degrees of renal function. J Antimicrob Chemother 1989;23:869-73.
35. Hoffler DK, Joeppe P, Naumann E, et al. Pharmacokinetics of teicoplanin haemodialysis patients. Infection 1991;19:324-7.
36. Hillaire-Buys D, Peyriere H, Lobjoie E, et al. Influence of arteriovenous haemofiltration in teicoplanin elimination. Br J Clin Pharmacol 1995;40:95-7.
37. Kacet N, Dubos JP, Roussel-Devallez M, et al. Teicoplanin and amikacin in neonates with staphylococcal infection. Pediatr Infect Dis J 1993;12:510-3.
38. Rybak MJ, Lerner SA, Levine DP, et al. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother 1991;35:696-700.
39. Steer J, Papini R, Wilson APR, et al. Pharmacokinetics of a single dose of teicoplanin in burn patients. J Antimicrob Chemother 1996; 47:545-53.
40. Lortholary O, Tob M, Rizzo N, et al. Population pharmacokinetic study of teicoplanin in severely neutropenic patients. Antimicrob Agents Chemother 1996;40:1242-7.
41. MacGowan AP, McMullin CM, White LO, et al. Serum monitoring teicoplanin. J Antimicrob Chemother 1992;30:399-402.
42. Edwards DJ, Pancorbo S. Routine monitoring of serum vancomycin concentrations: Waiting for proof of its value. Clin Pharmacol 1987;6:652-4.
43. Rodvold KA, Zofuka H, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: Can waiting be justified? Clin Pharmacol 1987;6:655-8.
44. Freeman CD, Quintilani R, Nightingale CH. Vancomycin therapeutic drug monitoring: Is it necessary? Ann Pharmacol 1993;27: 594-8.
45. Cantu TG, Yamanaka-Yuen Na, Leitman PS. Serum vancomycin concentrations: Reappraisal of their clinical value Clin Infect Dis 1994;18:533-43.
46. Moellering RC. Editorial: Monitoring serum vancomycin levels: Climbing the mountain because it is there. Clin Infect Dis 1994; 18:544-6.
47. Faber BF, Moellering RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983;23:138-41.
48. Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 1994;28:1335-9.
49. Fernandez de Gatta MD, Calvo MV, Hernandez JM, et al. Cost effectiveness analysis of serum vancomycin concentration monitoring in patients with haematologic malignancy. Clin Pharmacol Ther 1996;60:332-40.
50. Zimmerman AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcome in patients with Gram-positive bacteraemia. Pharmacotherapy 1995;15:85-91.
51. Rybak MJ, Capelletty MJ, Ruffing RC, et al. Influence of vancomycin serum concentrations on the outcome of patients being treated for Gram-positive infections. Abstr 37th Intersci Conf Antimicrob Agents Chemother 1997;A46.
52. Wilson APR, Gruneberg RN. Safety. In: Teicoplanin: The first decade. Abingdon, UK: The Medicine Group 1997:137-44.
53. Leport C, Perronne C, Massip P, et al. Evaluation of teicoplanin for treatment of endocarditis caused by Gram-positive cocci. Antimicrob Agents Chemother 1989;33: 871-6.
54. Greenberg RN. Treatment of bone, joint and vascular-access-associated Gram-positive bacterial infections with teicoplanin. Antimicrob Agents Chemother 1990;35:2392-7.
55. Rybak MJ, Cappelletty DM, Kang SL, et al. Pharmaco-dynamic evaluation of teicoplanin versus vancomycin in the treatment of Gram-positive bacteraemia and endocarditis. Abstr 36th Intersci Conf Antimicrob Agents Chemother 1996;A36.
56. MacGowan A, White L, Reeves D, et al. Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. J Infect Chemother 1996;2:197-208.
57. MacGowan AP, White LO, Reeves DS, et al. Teicoplanin in Staphylococcus aureus septicaemia: Relationship between trough serum levels and outcome. 37th Intersci Conf Antimicrob Agents Chemother 1997;A45.
58. Wilson APR, Gruneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994;4:S1-30.
59. Mulhern JG, Braden GL, O'Shea MH, et al. Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am J Kidney Dis 1995;25:611-5.